Skip to main content
HighRiskPaymentProvider.comPayment provider reviews

Peptide payments

Peptide payment processing

Peptide sellers cannot be underwritten from a category name alone. A research-reagent supplier, telehealth clinic, compounding pharmacy, outsourcing facility, manufacturer, and online drug seller operate under different product, licensing, prescribing, fulfillment, and payment conditions.

Last reviewed

Decision brief

Classify the exact peptide activity before seeking payments

Use this page when

Product status, intended use, claims and buyer type may place the activity outside ordinary ecommerce underwriting.

  1. Product status

    Identify what is sold, how it is labeled and whether the activity is research, compounding, clinical, prescription or consumer retail.

  2. Legal route

    Confirm the applicable regulator, license, prescription and distribution requirements for every market.

  3. Payment disclosure

    Describe the activity literally to the provider and obtain written product-specific acceptance.

Do not submit a generic ecommerce file

  • Product list, labels, intended-use statements and claims
  • Licenses, prescriptions, facility and distribution evidence where applicable
  • Customer type, geography, fulfillment and refund controls
01

Underwriting follows the actual intended use

The first task is to identify what the product is, who buys it, how it is described, and what happens after checkout. A 'research use only' or 'not for human consumption' label does not settle the question if product pages, dosing references, testimonials, social posts, affiliates, or customer instructions indicate human use.

FDA warning letters show that the agency evaluates the full presentation of a peptide product when determining intended use. A payment provider will normally apply the same practical scrutiny because it must understand whether the merchant is selling laboratory material, a prescription drug, a compounded preparation, or an unapproved drug product.

A gateway does not determine product legality

Technical acceptance of a transaction is not approval of the product, prescription model, compounding activity, or destination. The merchant remains responsible for obtaining qualified legal and regulatory advice.

02

Separate approved drugs, compounding, and research supply

FDA-approved drugs, compounded drugs, and products sold only for legitimate laboratory research are not interchangeable. Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act place different conditions on pharmacy compounding and outsourcing facilities, including limits on bulk drug substances.

FDA also maintains information on bulk substances that may present significant safety risks. Before applying, a merchant should classify every SKU, route of administration, intended customer, prescription path, facility, supplier, and destination under the rules that actually apply. If that analysis is unresolved, a processor cannot fix it by assigning a different MCC.

03

Documents needed for peptide merchant underwriting

Standard entity, ownership, banking, and processing records remain necessary. Peptide underwriting adds a detailed product and supply-chain review because small differences in ingredient, form, intended use, and fulfillment can change the account's risk.

  • A complete SKU list with ingredient, concentration, dosage form, route of administration, intended use, customer type, label, price, and destination.
  • Supplier and manufacturer identities, invoices, batch records, certificates of analysis, storage and shipping controls, and recall procedures.
  • All product pages, search ads, email, affiliates, social content, testimonials, FAQs, dosing or reconstitution material, and customer-support scripts.
  • Pharmacy, facility, prescriber, telehealth, state, and DEA records where the business model requires them.
  • Prescription, patient onboarding, compounding, dispensing, fulfillment, refund, complaint, and adverse-event procedures where applicable.
04

Match the MCC and checkout to the contracted seller

Visa's public merchant standards identify MCC 5122 for drugs and drug proprietaries and MCC 5912 for drug stores and pharmacies, but those codes do not cover every peptide business and do not establish legality. The acquirer assigns the MCC from the merchant's actual principal activity.

The checkout should name the contracting seller, show the correct descriptor and product, and send funds to the approved bank account. If a clinic, online pharmacy, telehealth platform, laboratory supplier, or marketplace performs a separate role, the agreement should state which party sells, bills, dispenses, fulfills, refunds, and carries the chargeback.

05

Plan for product complaints and fulfillment exposure

Payment disputes can arise from unauthorized cards, an unfamiliar descriptor, delivery delay, cold-chain failure, damaged product, refund disagreement, or a mismatch between marketing and what arrived. In a prescription flow, identity, authorization, cancellation, and dispensing records may also matter.

Pricing, volume limits, settlement delays, and reserves are quoted after review. Confirm how refunds and negative balances are funded, whether the reserve is fixed or a rolling reserve, and what its cap and release schedule are. Then confirm what happens to settlement after a compliance inquiry, and which product, supplier, claim, license, or fulfillment changes require advance approval.

06

Questions for a peptide processing proposal

Ask for a written scope that names the products and business model. 'Peptides supported' is too broad to describe an account.

  • Which legal entity, products, intended uses, customer types, websites, facilities, states, countries, and marketing channels are approved?
  • What MCC will be assigned, and which acquiring bank or PSP owns the merchant relationship?
  • Does the approval cover only research sales, or also a clinic, pharmacy, prescription, telehealth, compounding, or fulfillment flow?
  • Which FDA, pharmacy, facility, prescriber, state, or DEA records must be maintained for this route?
  • What triggers a settlement hold, product suspension, reserve change, or account termination?

FAQ

Common questions

Does 'research use only' make peptide sales acceptable for processing?

Not by itself. FDA and payment underwriters can consider the entire presentation and actual sale, including product pages, claims, dosing references, testimonials, affiliates, customer communications, and fulfillment. The label must match the real intended use.

Can a compounding pharmacy use a general peptide merchant account?

The account should be underwritten for the licensed pharmacy or outsourcing-facility model, the specific products, prescribers, states, facilities, dispensing flow, and applicable 503A or 503B conditions. A general product-category approval is not enough.

What MCC applies to peptide sales?

It depends on the principal business. Drug wholesalers and pharmacies can fall under different MCCs, while a legitimate laboratory supplier may be classified differently. The acquirer assigns the code after reviewing the actual activity.

Will a COA and supplier invoice be enough for approval?

Usually not. Underwriting can also cover intended use, drug or compounding status, ownership, licenses, marketing, customer type, prescription and fulfillment flows, processing history, chargebacks, refunds, and settlement exposure.

Official references